Quick ReadPlain-language overview · read this first
Tempus AI sells de-identified oncology-testing data to pharma companies for R&D, running a "testing + data + AI" linkage. 2025 revenue was $1.272 billion, +83%; the story is real, the growth is real. Rating: Watch.
The problem is certainty, not the story. In 2025 operating cash flow was still a net outflow of $218 million, and owner earnings on a conservative basis were still negative, so the P/Owner Earnings valuation tool simply breaks down. At the current $43.93 and EV/Sales of 6.4x, it is cheaper than the equally cash-burning Natera/Guardant but pricier than the already-profitable Illumina: not deeply cheap, just not as expensive within a pricey peer group; the current price bets almost the entire optimistic scenario in.
The most fragile point is the terminal margin, not revenue: the 10-K admits that as foundation models grow stronger, pharma companies may no longer need to buy its data. Add acquisition-integration complexity, a dual-class structure giving the founder 57.9% voting power, and the dilution from newly issued $460 million of convertible notes, and the ideal buy range is $18-28, with the current price out of range.
LeadA real business with real customers and real growth, but still paying for "future success": 2025 revenue of $1.272 billion (+83%), NRR of about 126%, and Remaining TCV above $1.1 billion, yet operating cash flow was still a net outflow of $218 million and free cash flow stayed negative. What the current $43.93 price lacks is certainty, not story: the valuation prices in near-optimistic assumptions. Rating: Watch, with a more attractive entry range of $18–28.
Prices in the article are as of publication; see the valuation band above for the live price.
Bottom Line Up Front
Because you did not fill in your "objectives" or "risk tolerance," I make the following judgment using a long-term, conservatively value-oriented framework; if you are a high-risk growth investor, your conclusion can be somewhat more positive than mine, but in my view it still falls short of a "Buffett-style buy."
Preliminary rating: Watch.
Core judgment: Tempus AI is not a hard-to-understand, scam-style story; it genuinely has a real business, real customers, and real growth, and it owns a rare "diagnostics + clinical data + pharma services + AI applications" linked platform. In 2025 the company's revenue reached $1.272 billion, up 83% year over year, of which Diagnostics revenue was $955 million and Data and applications revenue was $316 million; 2025 Net Revenue Retention was about 126%, and signed Remaining Contract Value exceeded $1.1 billion, showing that its data business has a degree of stickiness. At the same time, the problem is equally clear: as of the end of Q1 2026, the company still has not proven it can steadily generate real, distributable cash flow. In 2025 operating cash flow was a net outflow of $218 million, and estimated from capital expenditures and capitalized software spending, free cash flow remained clearly negative. At the most recent available closing price of $43.93, the company's market capitalization is about $7.86 billion; this price looks more like paying for "a very successful future" than for "a cash machine that already exists today."
Is there a margin of safety at the current price: not obvious. Viewed through a Buffett-style framework, what the current price lacks is certainty, not story. Buying TEM now essentially means betting that data assets will convert into higher margins, that acquisitions such as Ambry/Paige/Deep 6 will integrate smoothly, that dilution will stay manageable, and that regulation and reimbursement will keep improving. Once any one of these fails to materialize, the rate of return gets compressed quickly.
Suitable investor type: better suited to aggressive growth investors who can accept high volatility and high valuation elasticity and are willing to keep tracking operating metrics; less suited to traditional long-term value investors who put "predictable cash flow, steady capital returns, and margin of safety" first.
Biggest uncertainties:
Whether the "moat" from data and AI applications can actually translate into long-term high margins, rather than just high growth.
After acquisition-driven growth, when operating cash flow truly turns positive, and whether it can stay positive afterward.
Whether dilution, the dual-class share structure, and convertible-bond financing will make "the company bigger" while per-share intrinsic value grows more slowly than expected.
One-sentence conclusion: Tempus AI may be a company with great potential, but at today's price it still does not look like a value investment with a sufficient margin of safety.
The Business and the Industry
What is the core business. Tempus currently has two main product lines: Diagnostics and Data and applications. Diagnostics is essentially an oncology and genetics testing business, providing NGS, PCR, pathology, and molecular diagnostic services to physicians, genetic counselors, research institutions, and pharmaceutical companies; Data and applications takes the de-identified clinical, molecular, and imaging data accumulated in the diagnostic process and sells it to pharmaceutical and biotech companies for drug development, clinical-trial matching, analytics services, and AI applications. In its own 10-K the company explicitly states that these two product lines reinforce each other: more diagnostics means a thicker data asset, and the more successful the data business, the more it in turn drives usage of the diagnostics business.
Who are the customers, and how does it charge. Diagnostics' direct customers are mainly healthcare providers and biopharma companies. Its charging models include third-party payer reimbursement, contract research testing, and direct billing. Data and applications' main customers are pharmaceutical and biotech companies, with revenue coming from data licensing, AI-assisted clinical-trial matching, and analytics services. In 2025 the Data business's Net Revenue Retention was about 126%, indicating that existing customers as a whole are still expanding their orders; as of the end of 2025, Remaining TCV exceeded $1.1 billion, including about $300 million of optional add-on contract value.
Is the revenue recurring, stable, and predictable. In my view this company is not a purely "one-and-done" business, but it is also by no means Coca-Cola-style, highly stable repeat consumption. Within Diagnostics, oncology testing and genetic screening have a degree of continuous demand, but reimbursement, test-category iteration, and order cadence affect collections and revenue recognition. On the Data and applications side, contract stickiness is relatively high, but the company itself notes in the 10-K that this business is affected by pharma budget cycles, and data revenue is usually weighted toward recognition in the second half of the year. In other words, it has recurrence, but its predictability is still medium, not high.
Cost structure and dependencies. Diagnostics costs come mainly from lab personnel, consumables, depreciation, logistics, and third-party lab services; Data and applications costs come more from data acquisition, cloud computing, royalties, and delivery personnel. In 2025 the company's total revenue was $1.272 billion, against cost of revenue of $474 million, implying by the statements a gross profit of about $798 million and a gross margin of about 62.7%, continuing to improve from about 55.0% in 2024. The problem is that the gross-margin improvement has not translated into positive free cash flow. On dependencies, the company discloses that no single customer accounts for a material share of revenue, which is a positive; but it also discloses that for certain lab materials, equipment, and services it depends on a single supplier, which is an operational fragility.
Can this business be understood. In a single sentence, it can be understood as: first do the testing, then accumulate high-value medical data, then sell the data and algorithms to pharma companies and clinical settings. This is not mystical. But it also blends lab services, clinical reimbursement, a pharma data business, medical software, and AI algorithms, so its complexity is clearly higher than that of a typical consumer, insurance, or industrial company. My understandability score: 3/5. I can understand what it does, but I cannot estimate the stability of its cash flow 10 years out as easily as I can for a mature toll road, an insurance company, or a seasonings maker.
Industry stage and competitive landscape. At the industry level, this is not a declining industry; it sits at the intersection of precision medicine, molecular diagnostics, and healthcare data services, still in a growth stage. The long-term direction of demand is positive: individualized cancer diagnosis and treatment, genetic screening, real-world data supporting drug development, clinical-trial matching, and AI-enabled diagnostics all have a long-term demand base. But the other side of this industry is that technology substitution is fast, regulation is heavy, reimbursement is critical, and competitors are many. The competitors Tempus lists in its 10-K include, on the Diagnostics side, Roche/Foundation Medicine, Caris, Guardant, Natera, NeoGenomics, Quest, and Labcorp, and on the data and clinical-trials side, Flatiron, IQVIA, ConcertAI, ICON, PPD, and Syneos. In other words, Tempus sits in a good industry, but by no means an easy race track.
Industry attractiveness score: 3/5. The growth space is large, but the barriers of capital, technology, reimbursement, and execution are all high, and the moat is still forming dynamically.
Moat and Management
Moat assessment. Following Buffett's usual breakdown, I think Tempus's most credible moat is not brand, nor extreme low cost, but data scale + the ability to structure multimodal data + embedding into the clinical workflow + pharma partnerships. In its 10-K the company describes its core selling point as connecting lab results with clinical data so that testing "gets smarter the more it is done," and explicitly says a network effect exists between the two business lines. In 2025 the Data business's NRR was about 126% and Remaining TCV exceeded $1.1 billion, which also shows these data assets are not without commercial value. On top of that, it has a partnership agreement with GSK carrying a minimum committed purchase of $180 million, running through 2027, plus an option for an additional up to $120 million during 2028–2030.
But to call this a "durable, unbreakable" moat, I think the evidence is not yet sufficient. There are three reasons. First, the Diagnostics race is intensely competitive in itself, and the rivals Tempus lists are heavyweight. Second, the pharma data business is not run by Tempus alone; Flatiron, IQVIA, ConcertAI, and others are in the same profit pool. Third, in its risk factors the company explicitly warns that the development of foundation models could in the future weaken customer demand for its data products; if customers ultimately no longer need to buy de-identified data from Tempus, the economic rent of the data moat could narrow.
Accordingly, my judgment on the various types of moat is as follows:
| Dimension | Assessment |
|---|---|
| Brand advantage | Has a degree of industry recognition, but is still far from a "strong brand premium" |
| Cost advantage | Shows signs of scale effects, but has not proven low enough to suppress peers |
| Scale advantage | Yes, especially in multimodal data accumulation and pharma partnerships |
| Network effect | In embryonic form; Diagnostics and Data reinforce each other |
| Switching costs | Pharma customers' existing projects, historical data structures, and integration processes create some stickiness |
| Channel advantage | Workflow embedding into hospitals and physicians is strengthening, but is still not an absolute advantage |
| Patent/regulatory barriers | There are barriers in medical-testing and algorithm-related settings, but they are not insurmountable |
| Data advantage | This is the most critical and most genuine source of advantage |
| Culture/operating capability | Execution looks strong from M&A and platform expansion, but is still being validated |
| Capital allocation capability | Medium; there is forward-looking positioning, but also dilution and financing-cost issues |
My moat-strength score: 3/5. More precisely, it is a "moat in the process of forming," not one already proven to be wide for 10 years.
Is the moat widening, stable, or narrowing. My judgment is that it currently leans toward widening, but the evidence is still not enough to conclude with high confidence. The 2025 acquisitions of Ambry, Paige, Deep 6, and OneOme did broaden Tempus's database and capability boundaries in genetics, digital pathology, clinical-trial matching, and pharmacogenomics. On the other hand, the acquisitions also made the quality of growth harder to read and sharply raised complexity. The moat may be widening, or it may just be piling up more assets together without forming a high enough unit-economic return.
Management credibility and shareholder alignment. Eric Lefkofsky is the founder, chairman, and CEO. The 2026 proxy shows he holds about 21.4% of the economic interest and all of the Class B shares, for about 57.9% of combined voting power, and that directors and officers as a group hold about 22.1% of the economic interest and 58.3% of the voting power. The upside is strong interest alignment, and management will not be easily driven by short-term market sentiment; the downside is equally clear: minority-shareholder governance rights are weak, and the dual-class structure significantly reduces external constraints.
Is capital allocation rational. I give it a medium score. On the positive side, management uses the money mainly on reinvestment and M&A, rather than paying dividends for show; in May 2026 the company issued $460 million of 0% convertible notes, explicitly to optimize its capital structure and repay the Ares credit facility, a step that is rational from an interest-cost standpoint. On the negative side, over the past two years the company's capital allocation has had a clear "build the platform big first, prove the returns later" style: the Ambry deal consideration was $600 million, of which $375 million was cash and $225 million stock; in 2025 it also acquired Paige and Deep 6. For a company that has not yet formed stable free cash flow, this pace of M&A amplifies the uncertainty of integration and capital returns.
Dilution is a very real problem. At the end of 2025, the company had 9.061 million granted but unsettled awards outstanding under its equity-incentive plan, plus 5.895 million shares still available to grant; its 2024 Equity Incentive Plan also carries an evergreen mechanism that automatically replenishes at 5% of total shares outstanding, and the ESPP has an arrangement that automatically increases at 2% of total shares. This means that even if the company's operations improve, per-share value growth could be dragged down by ongoing dilution. Add to that the $726 million of convertible notes already in place in 2025 and the new $460 million of convertible notes in 2026, and the potential expansion of the share count cannot be ignored.
My management and capital-allocation score: 3/5. There is vision, execution capability, and a highly aligned founder, but governance is not "shareholder-friendly," and capital allocation is on the aggressive side.
Financial Quality
Let me state the most important conclusion first: Tempus's financial statements look great on "growth" but are still far from passing the bar on "free cash flow." Revenue is growing fast and gross margin is improving, but operating cash flow and owner earnings are still negative. More importantly, the 2024 statements were strongly distorted by IPO-related stock-based compensation, and the 2025 statements were affected by the Ambry and other acquisitions, so the comparability of the statements is not ideal. Therefore, one cannot look only at "revenue doubling" and "Adjusted EBITDA improving"; one must watch cash flow, working capital, dilution, and per-share value.
| Metric | 2022 | 2023 | 2024 | 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue ($ million) | 320.7 | 531.8 | 693.4 | 1,271.8 | 348.1 |
| Revenue YoY | — | 65.8% | 30.4% | 83.4% | needs a comparable annualized figure |
| Gross margin | 40.6% | 53.8% | 55.0% | 62.7% | needs a comparable figure |
| Net margin | -90.4% | -40.3% | -101.8% | -19.3% | -36.2% |
| Operating cash flow ($ million) | -168.2 | -214.3 | -189.0 | -218.1 | about -73.3 |
| Estimated free cash flow (CFO − capex − capitalized software, $ million) | -186.6 | -248.9 | -211.1 | -245.3 | clearly negative |
| Period-end cash & cash equivalents + marketable equity securities ($ million) | needs supplementing | needs supplementing | needs supplementing | 759.7 | 639.1 |
| Rough period-end interest-bearing debt ($ million) | needs supplementing | needs supplementing | needs supplementing | around 1,239.5 | 933.9 |
| Weighted-average shares (million) | 63.0 | 63.3 | 119.8 | 174.3 | 178.9 |
In the table, the 2022–2023 data come mainly from Tempus's 2024 S-1 summary financial and cash-flow statements; the 2024–2025 data come mainly from the 2024 full-year results disclosure and the 2025 10-K; the Q1 2026 data come from the Q1 2026 10-Q and public earnings disclosures. Gross margin, net margin, and free cash flow are calculated from the figures in the public statements; where the company's basis differs from my calculation basis, the company's statements prevail.
Are the profits real cash profits, or accounting profits. At present it is closer to "accounting profit and non-GAAP metrics are improving, but real cash profit has not yet appeared." In 2024 the net loss was as high as $706 million, of which $548 million came from stock-based compensation and related payroll taxes, which significantly distorted GAAP net income; but even excluding such items, 2025 operating cash flow was still a net outflow of $218 million, showing that the problem cannot simply be blamed on accounting noise. In other words, Tempus's profit quality is improving, but it is not yet enough to prove that it is already a machine that steadily spits out cash.
Does growth require heavy capital investment. Looking only at fixed-asset capex, 2025 capex was $21 million and capitalized software was $6.216 million, whose share of revenue is actually not high; but if you include M&A, working-capital occupation, cloud resources, and R&D and sales investment together, this company's growth is very "capital-hungry." It is not heavy industry, but it is by no means a SaaS that can effortlessly turn revenue into free cash flow. In 2025 the company's net cash outflow for M&A reached $377 million.
Is the balance sheet sound. As of March 31, 2026, the company had $521 million in cash and cash equivalents, $118 million in marketable equity securities, and $2.135 billion in total assets; at the end of 2025 it had $728 million in convertible notes, $203 million in long-term debt, $209 million in convertible notes, and $100 million in revolving credit. Roughly estimated on the Q1 2026 basis, net debt is still around $300 million, and EBITDA has not yet steadily turned positive, so net debt/EBITDA and interest coverage do not look good, and strictly speaking are not very meaningful, because the denominator is far from "mature and stable." In May 2026 the company again issued $460 million of 0% convertible notes and repaid the Ares debt, which helps reduce the interest burden but also continues to build the valuation on top of future share price and future earnings.
Receivables, payables, inventory, and accounting risk. I have not pulled out the accounts receivable for every year in full from the materials I can currently verify, so I will not fabricate. What can be confirmed is that in both the 2024 and 2025 cash-flow discussions the company emphasized that changes in working capital clearly consumed cash; at the end of 2025 inventory was about $49.9 million, with inventory/work-in-progress up from the end of 2024; in Q1 2026 accounts payable fell from $81.99 million at the end of 2025 to $41.02 million, which is unfavorable for cash flow. Another point worth watching is that in the 2025 internal-control assessment by management and auditors, Ambry and Paige were excluded, together accounting for about 11% of total assets and 29% of total revenue in 2025. This does not indicate financial fraud, but it shows that the accounting and internal-control complexity of the post-acquisition integration period is rising.
My judgment on financial quality: If "financial quality" is understood as "growth speed + gross-margin improvement," it is making progress; if it is understood as "how much free cash flow each dollar of revenue turns into," it has not yet reached the standard a value investor wants.
Owner Earnings and Valuation
How to estimate owner earnings. The basic idea of Buffett-style Owner Earnings is:
Owner Earnings = net income + non-cash charges such as depreciation and amortization − maintenance capital expenditures − the increase in working capital needed to sustain operations
For a company like Tempus, the difficulty lies in two things. The first is whether stock-based compensation should be added back. My answer is: it cannot be mechanically added back, because for shareholders, ongoing stock-based compensation is essentially a cost, just paid in the form of dilution. The second is that the boundary between maintenance capex and growth capex is very blurry. Therefore, I can only give a conservative estimate, not a seemingly precise pseudo-number.
A conservative estimate of 2025 Owner Earnings. The 2025 net loss was -$245 million; operating cash flow was a net outflow of -$218 million; that year's capex was $21 million and capitalized software $6.216 million. Even granting that depreciation and amortization are relatively high, and that 2025 was affected by acquisition integration and some non-cash items, under a conservative framework 2025 owner earnings were still clearly negative, on the order of roughly -$250 million to -$350 million. The difference within this range mainly depends on whether you treat certain non-recurring items and part of the growth-related working-capital occupation as negligible. For a Buffett-style investor, what matters more is not the range's midpoint but the fact itself: it is not yet positive.
How many times Owner Earnings is the current valuation. The answer is: meaningless, or N.M. Because under the conservative basis owner earnings are negative. At the recent market cap of $7.86 billion, TEM is currently valued not as a "cash-flow machine" but as a "future platform-type, high-margin medical-AI asset."
At the most recent available close, TEM's share price was $43.93 and market cap about $7.86 billion. Roughly estimating from the Q1 2026 cash, marketable equity securities, and debt, enterprise value is about $8.16 billion, corresponding to a 2025 EV/Sales of about 6.4x; if we also factor in the $460 million of 0% convertible notes added in May 2026 and the Ares repayment, enterprise value is still roughly in the $8.4–8.5 billion range, corresponding to a 2025 EV/Sales of about 6.6–6.7x.
How to view relative valuation. The most comparable set is not pure software companies but the group of "molecular diagnostics / clinical data / precision-medicine platforms." Roughly estimating from recent market cap and 2025 revenue, Tempus's price-to-sales ratio is broadly below Natera and Guardant, but above the more mature, GAAP-profitable Illumina; if Exact Sciences is included, EXAS has weaker comparability due to M&A events and a different business structure, and can only be a reference. The key here is not "peers are all expensive, so it is not expensive," but rather: compared with equally high-valuation companies that are also growing, Tempus is not extremely cheap; and compared with companies that have already proven their earning power, it is not cheap enough to compensate for execution risk.
| Company | Recent market cap | 2025 revenue | Rough P/S | Notes |
|---|---|---|---|---|
| Tempus AI | $7.86 billion | $1.272 billion | about 6.2x | Still has not proven stable FCF |
| Natera | $26.37 billion | $2.306 billion | about 11.4x | More mature growth, but still high valuation |
| Guardant Health | $12.46 billion | $982 million | about 12.7x | Screening expectations lift the valuation |
| Illumina | $21.95 billion | $4.34 billion | about 5.1x | More mature, more solid profitability |
In the table, market caps come from recent market quotes; revenue comes from each company's official 2025 full-year disclosure. Because of differences in business structure, accounting basis, and growth stage, this is suitable only as a "valuation-framework reference," not for a one-size-fits-all conclusion.
Intrinsic-value estimate. Here I give three methods, but I must stress first: for a company like Tempus, still crossing the earnings inflection point, the valuation result is extremely sensitive to assumptions, and precision to the single dollar is false precision.
Method one: Owner Earnings discounting. Since current Owner Earnings are negative, I can only run scenario analysis for the case of "turning positive and scaling at some future point." My three scenarios are as follows:
| Scenario | Core assumptions | Estimated intrinsic value |
|---|---|---|
| Conservative | Revenue CAGR of about 10% over the next 10 years, Owner Earnings margin eventually reaching 10%, discount rate 12%, terminal growth 3% | about $8–15/share |
| Neutral | Revenue CAGR of about 12% over the next 10 years, Owner Earnings margin eventually reaching 15%, discount rate 10%, terminal growth 3% | about $20–30/share |
| Optimistic | Revenue CAGR of about 15% over the next 10 years, Owner Earnings margin eventually reaching 18%, discount rate 9%, terminal growth 3.5% | about $45–60/share |
These ranges are not "price forecasts"; they illustrate that at the rate of return a value investor requires, for the current price of $43.93 to hold, Tempus needs to be fairly close to the optimistic scenario. This is also the core reason I think the margin of safety is insufficient.
Method two: relative valuation. TEM's price-to-sales is not as high as Natera's or Guardant's, but it is not deeply cheap either. If over the next 3–5 years Tempus really thickens the margin and stickiness of Data and applications further, a price-to-sales of around 6x may not be outrageous; but if it ultimately looks more like a hybrid medical platform with "decent margins, mediocre cash flow, and ongoing reliance on financing and dilution," then this price is not cheap. In other words, relative valuation can only show that it is not at a bubble top; it cannot show that it has a margin of safety.
Method three: asset/liquidation value. This method is not friendly to Tempus. In Q1 2026 the company's total assets were $2.135 billion, including a large amount of goodwill and intangibles formed by acquisitions; at the same point in time, net intangible assets alone were about $331 million and goodwill about $470 million. If such assets are heavily discounted in a liquidation, Tempus's liquidation value provides almost no strong support to shareholders. Its value comes mainly from future cash flows, not from existing hard assets. This is also why I would not treat it as an asset-type stock where "you can mindlessly buy once it falls near book value."
Combined intrinsic-value range. In my view, a more reasonable expression is:
Conservative intrinsic-value range: $10–20/share
Fair intrinsic-value range: $20–35/share
Optimistic intrinsic-value range: $45–60/share
Viewed against the current $43.93:
Relative to the conservative range: clearly overvalued;
Relative to the fair range: on the high side or overvalued;
Relative to the optimistic range: close to the lower bound.
Therefore my price judgment is:
Ideal buy range: $18–28/share
Acceptable holding range: $28–38/share
Clearly overvalued range: above $50/share
Current price: $43.93, closer to an "optimistic-expectation price" than a "margin-of-safety price."
Margin of Safety, Risks, and the Bear Case
Is the margin of safety sufficient. My answer is clear: it is not sufficient. Not because Tempus has no prospects, but because realizing its value requires several fragile assumptions to hold at once: revenue keeps growing fast, the Data business maintains high NRR, Ambry/Paige/Deep 6 integrate smoothly, the reimbursement environment keeps improving, operating cash flow turns positive as soon as possible, and equity dilution stays controllable. If any one deviates, the central return at the current price shifts down.
The most fragile valuation assumption. Not revenue growth, but the terminal margin. The market can usually tolerate short-term losses at a growth company, provided the future margin can be good enough. Tempus's current bull case is essentially a bet that once the data business, AI applications, and diagnostic capabilities are combined, they can form a higher long-term margin than a traditional lab. If it turns out to be just a platform with a little more software than a traditional lab but still dragged down by reimbursement and sales investment, then a price-to-sales above 6x lacks support.
The most important risks. First, competition risk: the rivals Tempus faces include both diagnostics leaders and pharma-data and CRO leaders, so the track is not a blue ocean. Second, technology-substitution risk: the company itself admits in the 10-K that the deployment of foundation models could in the future weaken customer demand for its de-identified data products. Third, regulatory and reimbursement risk: Diagnostics relies heavily on third-party payer reimbursement, and pricing power is not fully in its own hands. Fourth, acquisition-integration risk: a large part of the 2025 growth came from Ambry consolidation, and if integration goes poorly, both revenue quality and cash flow will suffer. Fifth, financing and dilution risk: dual-class shares, ongoing stock-based compensation, and convertible notes could all make per-share value grow more slowly than corporate scale. Sixth, rising accounting and internal-control complexity: the 2025 internal-control assessment excluded Ambry and Paige.
The strongest bear case. I would sum up the bear logic in one sentence: "Tempus is not a cheap monopoly asset; it is a multi-business platform integration story, wrapped in a high valuation, that is still burning cash and diluting." This view is not absurd. Bears would say: the 2025 revenue surge was driven mainly by the Ambry acquisition; the 2024 GAAP loss was distorted by IPO-related equity expenses, masking the real unit-economic quality; 2025 operating cash flow was still -$218 million, showing the "earnings inflection point" has not truly been crossed; and although the data business looks attractive, its real long-term pricing power and terminal margin remain unproven.
What facts would overturn my Watch stance and turn me positive. If the following combination appears over the next two to three years, I would clearly raise the rating: first, operating cash flow steadily turns positive, and free cash flow turning positive no longer depends on one-off working-capital swings; second, the NRR of Data and applications stays stable at a high level while TCV keeps growing; third, the pace of share dilution slows markedly; fourth, after the acquired assets complete integration, gross-margin gains reach per-share cash flow rather than stopping at Adjusted EBITDA.
What facts would prove the judgment wrong, which I should acknowledge. Conversely, if the following occur, I would conclude that "this is not a business worth holding for the long term":
Data-business NRR clearly falls below 110% and stays there for several quarters.
TCV growth stalls, while revenue relies more on one-off projects.
Operating cash flow remains sharply negative after 2027.
Per-share dilution keeps clearly outpacing revenue and gross-margin growth.
The reimbursement environment reverses, especially the unit price and coverage scope of oncology testing or genetic screening being compressed.
The acquired assets expose clear internal-control or integration problems.
The largest permanent-capital-loss scenario. It is not a short-term halving of the share price, but this company ultimately proving that it can only sustain growth through M&A and financing, and struggles to turn platform scale into stable per-share cash flow. In that case, even if revenue keeps growing, shareholder returns may not be good, and could even produce years of low returns due to long-term dilution and multiple compression.
Comparison, Checklist, and Final Recommendation
Comparison with other opportunities. If you compare Tempus with a broad-based index, my view is that it is not the kind of "certain asset" clearly superior to the index, but a high-volatility, high-divergence, high-execution-risk single-company bet. Against the roughly 4.47% risk-free yield of the 10-year Treasury, Tempus currently has no positive owner-earnings yield, so buying it gets you not a cash return but a long-term option on future high growth and high margins. For some growth investors this is fine; for a long-term value investor, it usually means you must either demand a lower price or wait for cash flow to become clearer.
Checklist
| Check item | Assessment |
|---|---|
| Can I understand this business | Pass |
| Does it have long-term stable demand | Pass |
| Does it have a durable moat | Uncertain |
| Does it have pricing power | Uncertain |
| Can it generate stable free cash flow | Fail |
| Is its return on capital excellent | Fail |
| Is management trustworthy | Uncertain |
| Is capital allocation rational | Uncertain |
| Is the balance sheet sound | Uncertain |
| Is the valuation below intrinsic value | Fail |
| Is the margin of safety sufficient | Fail |
| Does long-term holding let me rest easy | Fail |
| Which key facts would make me sell | See "signals triggering reassessment" below |
| Am I buying only because of the price or emotion | Needs self-check; emotion-driven decisions not advised now |
The above judgments are based comprehensively on the company's business structure, cash flow, financing and governance arrangements, and the degree to which the current valuation front-loads the future.
【Final Rating】 Watch
【One-Sentence Investment Thesis】 Tempus AI owns a rare and attractive prototype of a medical-data platform, but until it proves it can sustainably generate positive owner earnings, the current price lacks a sufficient margin of safety.
【Core Bull Reasons】
Diagnostics and Data and applications reinforce each other, and the business logic is genuinely real.
Revenue grew strongly in 2025, with 2025 NRR of about 126% and Remaining TCV above $1.1 billion.
After acquiring Ambry, Paige, Deep 6, and others, data breadth and product boundaries expanded clearly.
The 2026 0% convertible notes replacing high-cost debt is an improvement from a cost-of-capital standpoint.
The founder's shareholding and voting power are both high, so management will not easily make short-term decisions on a quarterly basis.
【Core Bear Reasons】
Under a conservative basis, owner earnings are still negative, and P/Owner Earnings does not hold.
2025 operating cash flow was still a net outflow of $218 million, and free cash flow was clearly negative.
Part of the 2025 growth came from M&A, and the organic quality and integration effect still need observation.
Dual-class shares, evergreen incentives, and convertible notes all imply future per-share dilution risk.
The current valuation is closer to an "optimistic-expectation price" than a price that "can withstand mistakes."
【Key Assumptions】
The customer stickiness and order-expansion trend of Data and applications can be maintained.
The integration of Ambry/Paige/Deep 6/OneOme will not drag down cash flow and internal controls.
Medicare/commercial-insurance coverage and pricing for key testing products will not deteriorate.
The pace of dilution will ultimately be lower than the growth rate of per-share intrinsic value.
【Fair Buy Price】 I would treat $18–28/share as a more attractive entry range; $28–38/share is barely open to discussing a small long-term tracking position; at the current $43.93 I do not think there is a sufficient margin of safety. The basis is that, at the discount rate a value investor requires, only long-term assumptions close to the optimistic scenario can support the current price.
【Target Holding Period】 If bought in the future, it is suitable to view over 5–10 years or even longer; but only after it first crosses the "prove the cash flow" stage. Treating it now as a "buy it and close the account for 5 years" asset is not something I am comfortable with.
【Expected Annualized Return】 This is a subjective estimate based on the current price, not a return promise:
Conservative scenario: -5% to 2%
Neutral scenario: 4% to 8%
Optimistic scenario: 10% to 15% The reason the ranges are not high is that the current price has already front-loaded a considerable part of the success.
【Maximum Loss Risk】 If the market re-prices Tempus from a "future high-margin platform" to a "complex, diluting, high-investment hybrid medical-services company," the central valuation will shift down significantly. In an extreme case, if growth slows, cash flow keeps failing to turn positive, and acquisitions erode value, a drawdown of 50% or more in the share price is not hard to imagine; this does not necessarily mean the company goes bankrupt, but it would mean the investment logic was wrong.
【Tracking Metrics】
The NRR of Data and applications.
Remaining TCV and its growth rate.
Whether operating cash flow and free cash flow keep improving.
Diagnostics gross margin and Data gross margin.
Changes in share count and the scale of stock-based-compensation grants.
The integration progress of Ambry/Paige/Deep 6.
Changes in key reimbursement policies and unit prices.
Renewals and expansions of major pharma partnerships.
The gap between Adjusted EBITDA and GAAP cash flow.
Internal controls, audit opinions, and potential restatement risk.
【Signals Triggering Reassessment】
NRR clearly falls below 110% and stays there.
TCV stalls or retreats.
Operating-cash-flow improvement stalls.
Dilution significantly outpaces revenue growth.
Reimbursement for key tests is compressed.
Acquired assets expose internal-control or accounting problems.
The company again takes on large debt or issues shares, but per-share value does not improve in step.
【Open Questions and Limitations】 This analysis has three main limitations: first, Tempus has been public for a short time, with limited long-term public reporting history; second, 2024 was strongly distorted by IPO-related stock-based compensation, and 2025 was affected by M&A, lowering year-over-year comparability; third, the estimates of "maintenance capex" and "normalized owner earnings" cannot be as high-precision as for a mature company. These uncertainties themselves are an important reason I do not give a "Buy" rating.
【Final Recommendation】 Coolly put, Tempus AI is worth researching and worth putting on a watch list, but today it looks more like a growth stock that needs to prove itself than a value stock that already shows a clear margin of safety. If you hold to Buffett-style standards, I would advise: wait for a lower price, or wait for clearer cash flow, before acting.
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free